The Impact of Biosimilars on the Innovator Market

The reduction is expected to be “substantially completed,” the San Diego-based company said, in the second quarter of 2025.

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.

Data from a Phase III study that evaluated lazertinib, in combination with amivantamab, in comparison to osimertinib as a first-line treatment resulted in the EC’s decision.

The company’s investments in Canada since 2023 have now resulted in the creation, or potential thereof, of 1200 new job positions.